Emergent BioSolutions (NYSE:EBS) Upgraded at StockNews.com

StockNews.com upgraded shares of Emergent BioSolutions (NYSE:EBS) from a hold rating to a buy rating in a research report report published on Thursday.

Several other equities research analysts have also recently issued reports on EBS. Rodman & Renshaw reissued a “buy” rating and set a $16.00 target price on shares of Emergent BioSolutions in a research note on Friday, September 13th. Benchmark raised their price objective on Emergent BioSolutions from $8.00 to $12.00 and gave the stock a “buy” rating in a research report on Thursday, November 7th.

Emergent BioSolutions Stock Down 2.4 %

Shares of NYSE EBS opened at $8.48 on Thursday. The company has a market capitalization of $459.45 million, a P/E ratio of -2.07 and a beta of 1.59. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.88 and a quick ratio of 1.47. The company has a 50 day simple moving average of $9.35 and a 200-day simple moving average of $8.70. Emergent BioSolutions has a 1 year low of $1.42 and a 1 year high of $15.10.

Hedge Funds Weigh In On Emergent BioSolutions

A number of hedge funds have recently made changes to their positions in EBS. CWM LLC raised its position in Emergent BioSolutions by 32,706.7% in the second quarter. CWM LLC now owns 4,921 shares of the biopharmaceutical company’s stock valued at $34,000 after purchasing an additional 4,906 shares during the period. Meeder Asset Management Inc. acquired a new stake in shares of Emergent BioSolutions in the second quarter valued at $41,000. Price T Rowe Associates Inc. MD grew its stake in shares of Emergent BioSolutions by 22.6% in the first quarter. Price T Rowe Associates Inc. MD now owns 23,943 shares of the biopharmaceutical company’s stock valued at $61,000 after buying an additional 4,409 shares in the last quarter. Verus Capital Partners LLC purchased a new stake in shares of Emergent BioSolutions in the 2nd quarter valued at $68,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new position in Emergent BioSolutions during the 2nd quarter worth about $93,000. Hedge funds and other institutional investors own 78.40% of the company’s stock.

About Emergent BioSolutions

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.